Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials-Reference-Cited by-同舟云学术

Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials

Published:2022-02 Issue:1 Volume:7 Page:100396
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Szeto C.W.,Kurzrock R.,Kato S.,Goloubev A.,Veerapaneni S.,Preble A.,Reddy S.K.,Adashek J.J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference58 articles.

1. Primary, adaptive, and acquired resistance to cancer immunotherapy;Sharma;Cell,2017

2. Immuno-oncology clinical trial design: limitations, challenges, and opportunities;Baik;Clin Cancer Res,2017

3. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval;Jardim;J Natl Cancer Inst,2015

4. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials;Schwaederle;J Clin Oncol,2015

5. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis;Schwaederle;JAMA Oncol,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy;iScience;2024-04

2. LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes;American Journal of Cancer Research;2024

3. Adaptation and Experimental Validation of Clinical RNA Sequencing Protocol Oncobox for MGI DNBSEQ-G50 Platform;Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry;2023-12

4. Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting;Pharmacological Research;2023-10

5. LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics;Cancer Medicine;2023-05-03